2. Signaling Pathways
  3. Stem Cell/Wnt
  4. Wnt

Wnt

Wnt

Related Products

PDF 1.16 MB

The Wnt signaling pathways are a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three Wnt signaling pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the protein Dishevelled inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell, and the noncanonical Wnt/calcium pathway regulates calcium inside the cell. The clinical importance of Wnt signaling pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes.

Wnt Isoform Specific Products:

Wnt Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148055
    Wnt/β-catenin agonist 3
    		Activator 99.87%
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis.
    Wnt/β-catenin agonist 3
  • HY-168593
    PROTAC KDM3 degrader-1
    		Inhibitor 99.07%
    PROTAC KDM3 degrader-1 (Compound 4) is a CRBN-recruiting PROTAC designed based on the IOX1 (HY-12304) scaffold. PROTAC KDM3 degrader-1 selectively degrades the KDM3A and KDM3B proteins, thereby inhibiting the Wnt/β-catenin signaling pathway. PROTAC KDM3 degrader-1 significantly suppresses the self-renewal capacity of colorectal cancer stem cells and inhibits the growth of colorectal cancer tumors. PROTAC KDM3 degrader-1 is suitable for research on colorectal cancer (Target protein ligand (Pink): HY-12304; linker (Black): HY-22335; Conjugate of E3 ligase ligand and linker: HY-112599; E3 ligase (Blue): HY-41547).
    PROTAC KDM3 degrader-1
  • HY-115539
    Windorphen
    		Inhibitor 99.75%
    Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP.
    Windorphen
  • HY-18285
    Longdaysin
    		Inhibitor 99.83%
    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of  5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively.
    Longdaysin
  • HY-160765
    WNTinib
    		Inhibitor 99.95%
    WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation.
    WNTinib
  • HY-147519
    ARUK3001185
    		Activator 99.28%
    ARUK3001185 is a potent, selective, orally active and brain-penetrant inhibitor of Notum (IC50 = 6.7 nM). ARUK3001185 can restore Wnt signaling in the presence of Notum in vitro. ARUK3001185 is selective against serine hydrolases, kinases, and drug targets. ARUK3001185 can be used to research the role of Notum plays in diseases.
    ARUK3001185
  • HY-W100287
    Murrayafoline A
    		Inhibitor 99.73%
    Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
    Murrayafoline A
  • HY-100408
    GNF-6231
    		Inhibitor 99.63%
    GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction.
    GNF-6231
  • HY-112799
    DK419
    		Inhibitor 99.86%
    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.
    DK419
  • HY-136073
    Wnt pathway activator 2
    		Activator 99.38%
    Wnt pathway activator 2 (compound 2) is a potent Wnt activator with an EC50 of 13 nM.
    Wnt pathway activator 2
  • HY-B0194A
    Tizanidine hydrochloride
    		Inhibitor 99.93%
    Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α2-adrenoceptor agonist (IC50 = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).
    Tizanidine hydrochloride
  • HY-P1454A
    Fz7-21 TFA
    		Antagonist 98.12%
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids.
    Fz7-21 TFA
  • HY-151463
    CDK8-IN-11
    		Inhibitor 98.20%
    CDK8-IN-11 is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 can be used in the research of colon cancer.
    CDK8-IN-11
  • HY-N0150R
    Monensin sodium (Standard)
    		Inhibitor
    Monensin (sodium) (Standard) is the analytical standard of Monensin (sodium). This product is intended for research and analytical applications. Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.
    Monensin sodium (Standard)
  • HY-108442
    JW67
    		Inhibitor 98.15%
    JW67 inhibits the canonical Wnt signaling with an IC50 of 1.17μM. JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth.
    JW67
  • HY-102067
    3289-8625
    		Inhibitor
    3289-8625 is an inhibitor of the PDZ domain of Dishevelled (Dvl) protein (Kd=10.6 μM) and has an inhibitory effect on Wnt signaling. In addition, 3289-8625 can slow the growth of prostate cancer PC-3 cells (IC50=12.5 μM). 3289-8625 can be used in the study of embryonic development and cancer.
    3289-8625
  • HY-102028
    KY1220
    		98.0%
    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway, with an IC50 of 2.1 μM in HEK293 reporter cells.
    KY1220
  • HY-121993
    Combretastatin A-1
    		Inhibitor
    Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects.
    Combretastatin A-1
  • HY-P10392B
    aStAx-35R TFA
    		Inhibitor 99.18%
    aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells.
    aStAx-35R TFA
  • HY-117233
    UU-T02
    		Inhibitor 99.63%
    UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM. UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells.
    UU-T02
Cat. No. Product Name / Synonyms Application Reactivity
Wnt Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.